Specialist and experienced pricing and market access consultancy
We will develop and implement a successful launch strategy for your product.
We build payer focussed pricing and market access strategies to enable commercial success.
We provide engaging training solutions that ensures your organisation stays ahead of the ever-changing market access landscape.
Unifying our internal strengths and external partnerships helps solve your pricing and market access challenges to drive patient access of your pharmaceutical products.
Clearly and concisely communicate key scientific, economic and commercial messages to enable company employees to effectively communicate the product’s value.
Individual solutions to suit you
We adapt our working style to reflect your needs
We have a wealth of practical knowledge & experience within the pharma industry & HTA bodies
We react quickly and effectively to provide the best support possible
We’re thrilled to announce our participation at World Orphan Drug Congress Europe 2024 in Barcelona …
Read moreWe’re delighted to announce our participation at ISPOR Europe 2024 in Barcelona this November. We’ll…
Read moreSpain is set to implement a comprehensive reform to its law of guarantees and rational use of medici…
Read moreAUTHORS: Amrit Kaliasethi, Tia Kwong, Mariam Bibi OBJECTIVES In 2013, England’s National Ins…
Read moreAUTHORS: Amy Boyers, Solen Monteil, Mariam Bibi OBJECTIVES Early Access Programmes (EAPs) prov…
Read moreThe European Commission’s 4th implementing act outlines how health tech developers can obtain early …
Read moreWe examine how real-world evidence strategies help address uncertainties in rare disease treatments …
Read moreAchieving HTA approval for orphan drugs requires strategic planning, early engagement, strong eviden…
Read moreThe recent appraisal by the National Institute for Health and Care Excellence (NICE) for Iptacopan, …
Read more